Comparative analysis of hepatitis c recurrence and fibrosis progression between deceased-donor and living-donor liver transplantation: 8-year longitudinal follow-up

Transplantation

Volumn 92, Issue 4, 2011, Pages 453-460

  Jain, Ashokkumar ^a   Singhal, Ashish ^a   Kashyap, Randeep ^b   Safadjou, Saman ^b   Ryan, Charlotte K ^b   Orloff, Mark S ^b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Deceased; Donor; Fibrosis; HCV; Liver; Living; Recurrence; Survival; Transplant

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; GAMMA GLUTAMYLTRANSFERASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; PREDNISONE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGRAFT; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CADAVER DONOR; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DONOR AGE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAFT SURVIVAL; HEPATITIS ACTIVITY INDEX; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; LIVING DONOR; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MELD SCORE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENT INFECTION; RETRANSPLANTATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SURVIVAL RATE;

ADULT; AGED; ANTIVIRAL AGENTS; CADAVER; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; LIVING DONORS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 80051798998     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182259282     Document Type: Article

References (45)

1. United Network for Organ Sharing. Available at: http://www.unos.org. Accessed September 21, 2010.
2. Adam R, McMaster P, O'Grady JG, et al. Evolution of liver transplantation in Europe: Report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231.
3. Marcos A. Right lobe living donor liver transplantation: A review. Liver Transpl 2000;6:3.
4. Williams R, Alisa A, Karani J, et al. Living related adult-to-adult liver transplantation: Meeting the donor shortage. Antiviral Res 2001;52:217.
5. Malago M, Testa G, Marcos A, et al. Ethical considerations and rationale of adult-to-adult living donor liver transplantation. Liver Transpl 2001;7:921.
6. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis Crecurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004;40:699.
7. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003;9:1028.
8. Thuluvath PJ, Yoo HY. Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received deceased donor transplantation. Liver Transpl 2004;10:1263.
9. Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech Dev 2003;120:117.
10. Zimmerman MA, Trotter JF. Living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003;9:S52.
11. Schiano TD, Branch AD, Chung RT, et al. HCV RNA levels after liver transplantation: Cadaveric versus live donor. Hepatology 2002;36:306A.
12. Everson GT, Trotter J. Role of adult living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003;9:S64.
13. Bozorgzadeh A, Jain A, Ryan C, et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 2004;77:1066.
14. Russo MW, Galanko J, Beavers K, et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004;10:340.
15. Shiffman ML, Stravitz RT, Contos MJ, et al. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation. Liver Transpl 2004;10:1248.
16. Humar A, Horn K, Kalis A, et al. Living donor and split-liver transplants in hepatitis C recipients: Does liver regeneration increase the risk for recurrence? Am J Transplant 2005;5:399.
17. Schmeding M, Neumann UP, Puhl G, et al. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: A single-center study of 289 patients. Liver Transpl 2007;13:687.
18. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease inpatient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202.
19. Wali M, Harrison RF, Gow PJ, et al. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248.
20. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004;10:1240.
21. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004;41:830.
22. Rayhill SC, Wu YM, Katz DA, et al. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation 2007;84:331.
23. Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: Association with treatment of rejection. J Hepatol 1998;28:756.
24. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation database. Liver Transpl Surg 1999;5:S107.
25. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000;32:673.
26. Pelletier SJ, Raymond DP, Crabtree TD, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000;32:418.
27. Duclos-Vallee JC, Teicher E, Vittecoq D, et al. Liver transplantation for patients infected with both HIV and HCV or HIV and HBV [in French]. Med Sci (Paris) 2007;23:723.
28. Burak KW, Kremers WK, Batts KP, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362.
29. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005;42:448.
30. Hondo M, Kaneko S, Matsushita E, et al. Cell cycle regulation of hepatitis C virus internal ribosomal entry site-directed translation. Gastroenterology 2000;118:152.
31. Agnello V, Abell G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptors. Proc Natl Acad Sci USA 1999;96:12766.
32. Pak YK, Kamuch MP, Berrios D, et al. Activation of LDL receptor gene expression in Hep G2 cells by hepatocyte growth factor. J Lipid Res 1996;37:985.
33. Olthoff KM. Hepatic regenerationin living donor liver transplantation. Transplantation 2003;9:S35.
34. Manez R, Mateo R, Tabasco J, et al. The influence of HLA donorrecipient compatibility on the recurrence of HBV and HCV hepatitis after liver transplantation. Transplantation 1995;59:640.
35. Van Vlierberghe H, Troisi R, Colle I, et al. Hepatitis C infection-related liver disease: Patterns of recurrence and outcome in cadaveric and livingdonor liver transplantation in adults. Transplantation 2004;77:210.
36. Schiano TD, Gutierrez JA, Walewski JL, et al. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. Hepatology 2005;42:1420.
37. Guo L, Orrego M, Rodriguez-Luna H, et al. Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl 2006;12:560.
38. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007;13:122.
39. Maluf DG, Stravitz RT, Cotterell AH, et al. Adult living donor versus deceased donor liver transplantation: A 6-year single center experience. Am J Transplant 2005;5:149.
40. Selzner N, Girgrah N, Lilly L, et al. The difference in the fibrosis progression of recurrent hepatitis C after live donor liver transplantation versus deceased donor liver transplantation is attributable to the difference in donor age. Liver Transpl 2008;14:1778.
41. Cameron AM, Ghobrial RM, Hiatt JR, et al. Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg 2006;244:563.
42. Papatheodoridis GV, Barton SG, Andrew D, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens. Gut 1999;45:427.
43. Jain A, Mohanka R, Orloff M, et al. Intravenous Mycophenolate Mofetil with low-dose oral tacrolimus and steroid induction for live donor liver transplantation. Exp Clin Transplant 2005;3:361.
44. Jain A, Sharma R, Ryan C, et al. Potential immunological advantage of intravenous mycophenolate mofetil with tacrolimus and steroids in primary deceased donor liver transplantation and live donor liver transplantation without antibody induction. Liver Transpl 2008;14:202.
45. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696.